Certified Researchers

Blood Glucose Monitoring Market Summary

The Global Blood Glucose Monitoring Market size was valued at USD 18.81 Billion in 2024, and the market is projected to grow from USD 20.38 Billion in 2025 to USD 45.46 Billion by 2035, registering a CAGR of 8.35% during the forecast period 2025–2035. North America led the market in 2025 with over 45% share, generating around USD 8.46 Billion in revenue.

The global market is witnessing strong growth due to the rapidly increasing global diabetic population, rising awareness regarding preventive healthcare, and growing adoption of continuous glucose monitoring technologies. Expanding home-based diabetes management and integration of smart digital monitoring solutions are further accelerating long-term market demand.

According to the World Health Organization, nearly 830 million people were living with diabetes globally in 2024, compared with approximately 200 million cases in 1990. WHO also reported that diabetes directly contributed to over 1.6 million deaths annually, highlighting the growing need for regular glucose monitoring technologies and advanced diabetes management solutions worldwide.

Key Market Trends & Highlights

The Blood Glucose Monitoring Market is experiencing a transformative shift towards advanced monitoring technologies and integrated health solutions.

The rise of Continuous Glucose Monitoring Systems is reshaping patient management strategies in diabetes care.
Integration with mobile health applications enhances user engagement and data accessibility for patients and healthcare providers.
North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing area for blood glucose monitoring solutions.
The increasing prevalence of diabetes and technological advancements in monitoring devices are driving market growth and innovation.

Market Size & Forecast

2024 Market Size	18.81 (USD Billion)
2035 Market Size	45.46 (USD Billion)
CAGR (2025 - 2035)	8.35%

Major Players

Companies such Abbott (US), Roche (CH), Medtronic (US), Dexcom (US), Bayer (DE), Johnson & Johnson (US), Ascensia Diabetes Care (DE), Terumo (JP), Sanofi (FR) are some of the major participants in the global market.

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Blood Glucose Monitoring Market Trends

The Blood Glucose Monitoring Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing awareness of diabetes management. Continuous glucose monitoring systems are gaining traction, as they offer real-time data and reduce the need for frequent finger pricks. This shift towards more user-friendly and efficient monitoring solutions appears to be reshaping consumer preferences, leading to a growing demand for devices that integrate seamlessly with mobile applications.

Furthermore, the emphasis on personalized healthcare is likely to propel innovations in this sector, as patients seek tailored solutions that cater to their specific needs. In addition, the global market is witnessing a rise in the adoption of telehealth services, which facilitate remote patient monitoring and consultations. This trend suggests a potential shift in how diabetes care is delivered, making it more accessible and convenient for patients.

As healthcare providers increasingly recognize the importance of continuous monitoring, the market may see a surge in partnerships between technology firms and healthcare organizations. Overall, the Blood Glucose Monitoring Market is poised for growth, with emerging technologies and changing consumer behaviors playing pivotal roles in its evolution.

Rise of Continuous Glucose Monitoring Systems

Continuous glucose monitoring systems are becoming increasingly popular due to their ability to provide real-time glucose readings. This technology minimizes the discomfort associated with traditional methods and offers users a more comprehensive understanding of their glucose levels throughout the day.

According to the Centers for Disease Control and Prevention, approximately 38.4 million people in the United States were living with diabetes in 2024, representing nearly 11.6% of the total population. Additionally, over 97 million U.S. adults were identified with prediabetes, creating substantial demand for continuous monitoring technologies that support early intervention and improved glycemic control outcomes.

Integration with Mobile Health Applications

The integration of blood glucose monitoring devices with Mobile Health applications is enhancing user experience. These applications allow for better data tracking, personalized insights, and improved communication between patients and healthcare providers, fostering a more engaged approach to diabetes management.

According to the Institute for Health Metrics and Evaluation, diabetes ranked among the top 10 causes of global health burden in 2024, with millions requiring continuous long-term disease management. The increasing use of mobile-connected healthcare platforms is improving medication adherence, remote monitoring efficiency, and patient-provider communication, particularly among technologically active diabetic populations worldwide.

Growth of Telehealth Services

The expansion of telehealth services is transforming diabetes care by enabling remote monitoring and consultations. This trend indicates a shift towards more accessible healthcare solutions, allowing patients to manage their conditions effectively from the comfort of their homes.

According to the Pan American Health Organization, digital health adoption expanded significantly across the Americas following the pandemic, with multiple countries integrating telemedicine into chronic disease management programs. The increasing availability of remote healthcare services is strengthening demand for blood glucose monitoring technologies capable of supporting real-time patient monitoring and data-driven diabetes care.

Blood Glucose Monitoring Market Drivers

Increasing Prevalence of Diabetes

The rising incidence of diabetes is a primary driver for the Blood Glucose Monitoring Market. According to recent statistics, the number of individuals diagnosed with diabetes continues to escalate, with projections indicating that by 2030, approximately 578 million people will be affected. This alarming trend necessitates effective blood glucose monitoring solutions to manage the condition.

As diabetes becomes more prevalent, the demand for innovative monitoring devices, including continuous glucose monitors and smart meters, is likely to surge. Consequently, manufacturers are compelled to enhance their product offerings to cater to this growing population, thereby propelling the global market forward.

Government Initiatives and Support

Government initiatives aimed at combating diabetes and promoting health are pivotal in driving the Blood Glucose Monitoring Market. Various countries are implementing policies to enhance diabetes care, including subsidies for monitoring devices and funding for research and development. These initiatives not only improve access to blood glucose monitoring solutions but also encourage innovation within the industry.

For example, some governments are collaborating with healthcare providers to establish programs that facilitate early diagnosis and management of diabetes. Such supportive measures are likely to stimulate growth in the global market, as they create a conducive environment for both manufacturers and consumers.

Rising Health Awareness and Preventive Care

There is a growing emphasis on health awareness and preventive care, which is significantly influencing the Blood Glucose Monitoring Market. As individuals become more informed about the risks associated with diabetes and the importance of regular monitoring, the demand for blood glucose monitoring devices is likely to increase.

Educational campaigns and initiatives aimed at promoting healthy lifestyles are encouraging people to take proactive measures in managing their health. This shift towards preventive care is expected to drive the market, as more consumers seek reliable monitoring solutions to maintain optimal glucose levels and prevent complications associated with diabetes.

Technological Advancements in Monitoring Devices

Technological innovation plays a crucial role in shaping the Blood Glucose Monitoring Market. Recent advancements, such as the development of non-invasive glucose monitoring technologies and the integration of artificial intelligence in data analysis, are transforming how patients manage their diabetes. For instance, devices that utilize optical sensors or biosensors are gaining traction, offering users more convenient and accurate monitoring options.

The market is projected to witness a compound annual growth rate of around 6.5% over the next five years, driven by these technological enhancements. As a result, the global market is expected to expand significantly, attracting investments and fostering competition among key players.

Aging Population and Associated Health Challenges

The aging population presents a significant driver for the Blood Glucose Monitoring Market. As individuals age, the risk of developing diabetes and other chronic conditions increases, necessitating effective monitoring solutions. By 2030, it is estimated that the number of people aged 60 and above will reach 1.4 billion, many of whom will require regular blood glucose monitoring.

This demographic shift is likely to create a substantial demand for user-friendly and efficient monitoring devices tailored to the needs of older adults. Consequently, the global market is expected to adapt and innovate to meet the unique requirements of this growing segment.

Market Segment Insights

By Type: Self-Monitoring Blood Glucose Devices (Largest) vs. Continuous Glucose Monitoring Devices (Fastest-Growing)

In the Blood Glucose Monitoring Industry, Self-Monitoring Blood Glucose Devices currently dominate the landscape, accounting for the largest share of 62.4% among all segment values. This segment is pivotal for at-home diabetes management, providing patients with immediate feedback on their glucose levels. Following closely is the Continuous Glucose Monitoring Devices segment, which has seen rapid growth as it offers a more innovative and less invasive approach to glucose monitoring, catering to the increasing needs for regular monitoring without frequent finger pricks. The growth trends in this segment are driven by technological advancements and a rising prevalence of diabetes globally. Continuous Glucose Monitoring Devices have become particularly popular due to their ability to provide real-time data and alerts, enhancing patient engagement and improving glycemic control. Self-Monitoring Devices, while still dominant, must evolve to meet the changing needs of users who increasingly prefer comprehensive digital solutions that offer connectivity and data analytics to support their chronic condition management.

Self-Monitoring Blood Glucose Devices (Dominant) vs. Continuous Glucose Monitoring Devices (Emerging)

Self-Monitoring Blood Glucose Devices hold a dominant position in the market due to their established use and acceptance among patients. These devices are typically used for periodic glucose checks and are favored for their simplicity and cost-effectiveness. Conversely, Continuous Glucose Monitoring Devices represent an emerging technology, appealing to patients seeking a more automated solution. They provide continuous data tracking, allowing for more proactive diabetes management. As the landscape evolves, the integration of mobile technology and data analytics is expected to advance these devices further, enhancing user experience and improving clinical outcomes. The potential for remote monitoring and telehealth integration is a significant driver for growth in Continuous Glucose Monitoring Devices.

By Technology: Electrochemistry (Largest) vs. Optical Method (Fastest-Growing)

In the Blood Glucose Monitoring Market, the technology segment showcases a diverse array of methodologies, with electrochemistry leading the market share at 71.2%. This traditional technique relies on the electrochemical reaction of glucose in the blood, which has garnered widespread acceptance due to its reliability and accuracy. On the other hand, the optical method, though currently holding a smaller portion of the market, is rapidly gaining traction among consumers and healthcare providers alike due to its non-invasive nature, which appeals to a growing segment of users seeking pain-free monitoring options. As the demand for diabetes management solutions escalates, the growth drivers for both methods reveal insightful trends. The electrochemistry market, being well-established, benefits from continuous innovations aimed at improving device precision and user experience. Conversely, the optical method is set to experience accelerated growth propelled by advancements in sensor technologies and an increase in market players investing in research and development, resulting in the introduction of high-performance optical devices that are more competitive in terms of both cost and effectiveness.

Technology: Electrochemistry (Dominant) vs. Optical Method (Emerging)

Electrochemistry remains the dominant technology in the global market, primarily due to its longstanding reliability and proven accuracy in glucose measurement. Devices utilizing this technology are well-integrated within current medical practices, making it a trusted choice for both patients and healthcare professionals alike. Improvements in this segment emphasize miniaturization and enhancement of user interface, subsequently increasing consumer satisfaction and device adoption. Conversely, the optical method is emerging as an innovative alternative, especially appealing to users who prioritize non-invasive measurement techniques. This technology leverages advanced optical sensors to monitor glucose levels and is positioned to disrupt the market with its user-friendly applications. As R&D continues to advance optical methodologies, this segment is poised for significant growth, attracting new users and enhancing overall market dynamics.

By End User: Hospitals (Largest) vs. Homecare Settings (Fastest-Growing)

In the Blood Glucose Monitoring Industry, hospitals have established themselves as the largest segment, commanding a significant share of 58.3% due to their extensive patient base and integrated healthcare services. These settings utilize advanced monitoring technologies, ensuring accurate and timely management of diabetes, which is crucial for patient care. Homecare settings, on the other hand, are witnessing a rapid growth trend driven by the increasing preference for at-home health management solutions and more personalized patient care. The convenience of using blood glucose monitors at home has led to a surge in demand from patients seeking autonomy in their management of diabetes.

Hospitals (Dominant) vs. Homecare Settings (Emerging)

Hospitals remain the dominant end-user in the global industry due to their comprehensive infrastructure and ability to leverage advanced monitoring systems effectively. They benefit from access to specialized personnel and technology integration, which enhances patient outcomes significantly. Homecare settings represent an emerging segment on the rise, driven by evolving patient preferences for self-management and the advancement of user-friendly monitoring devices. The growth in this segment is supported by the aging population and a shift towards personalized healthcare solutions, making homecare solutions a viable alternative to traditional hospital visits. Together, these segments illustrate a dynamic shift in diabetes management, balancing the need for institutionalized care with the convenience of home-based monitoring.

By Application: Diabetes Management (Largest) vs. Obesity Management (Fastest-Growing)

The Blood Glucose Monitoring Market is significantly influenced by various applications, primarily Diabetes Management, Obesity Management, and Gestational Diabetes Monitoring. Among these, Diabetes Management holds the largest market share, accounting for 79.8%, driven by the increasing global prevalence of diabetes. This segment encompasses various tools and technologies tailored for individuals with diabetes, fostering a substantial portion of market activity. Obesity Management, while smaller in terms of market share, is rapidly gaining traction, reflecting a growing recognition of the relationship between obesity and blood glucose levels, therefore showcasing notable growth potential in the market.

Obesity Management: Emerging vs. Gestational Diabetes Monitoring: Stable

Obesity Management is becoming a more prominent application within the global market, largely due to rising obesity rates and the health implications associated with poor glucose regulation. This segment is considered emerging as more individuals seek proactive approaches to manage their weight and related health issues. On the other hand, Gestational Diabetes Monitoring remains a stable segment, essential for expecting mothers to maintain healthy blood sugar levels during pregnancy. Both segments highlight the evolving landscape of blood glucose management, where the emphasis is increasingly placed not just on management of diabetes, but also on preventing associated conditions through early intervention and monitoring.

Get more detailed insights about Blood Glucose Monitoring Market

Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America leads in the Blood Glucose Monitoring Market size, accounting for over 45% of the global revenue in 2024. The region's growth is driven by increasing diabetes prevalence, technological advancements, and supportive regulatory frameworks. The U.S. leads this market, followed closely by Canada, which contributes around 15% to the overall market. The rising demand for continuous glucose monitoring systems is a significant trend, supported by government initiatives promoting diabetes management.

According to the Centers for Disease Control and Prevention, more than 38.4 million Americans were diagnosed with diabetes in 2024, while approximately 97.6 million adults were living with prediabetes. Rising healthcare expenditure and growing awareness regarding preventive diabetes management are significantly accelerating demand for advanced blood glucose monitoring solutions throughout North America.

The competitive landscape in North America is robust, featuring key players like Abbott, Medtronic, and Dexcom. These companies are at the forefront of innovation, introducing advanced monitoring devices that enhance patient care. The presence of established healthcare infrastructure and a high level of awareness among patients further bolster market growth. Additionally, partnerships between technology firms and healthcare providers are expected to drive future advancements in this sector.

Europe : Emerging Market with Growth Potential

Europe Blood Glucose Monitoring Market size was valued at USD 5.64 billion in 2024, making it the second-largest regional market with a 30% share. The region's growth is fueled by rising diabetes cases, increasing healthcare expenditure, and a growing emphasis on preventive healthcare. Germany and France are the leading countries, together contributing around 20% to the market. Regulatory support for innovative medical devices is also a key driver, enhancing market accessibility and adoption.

According to the European Centre for Disease Prevention and Control, chronic disease prevention and digital healthcare initiatives have expanded significantly across European healthcare systems in recent years. Additionally, Eurostat estimates indicate that over 21% of Europe’s population was aged 65 years and above in 2024, increasing long-term demand for continuous glucose monitoring and home-based diabetes management technologies.

The competitive landscape in Europe is characterized by a mix of established players and emerging startups. Companies like Roche and Bayer dominate the market, focusing on developing user-friendly and efficient monitoring solutions. The presence of a well-established healthcare system and increasing patient awareness about diabetes management further support market growth. Collaborative efforts between governments and private sectors aim to improve diabetes care, paving the way for innovative solutions in the future.

Asia-Pacific : Rapidly Growing Market Segment

Asia-Pacific is witnessing rapid growth in the blood glucose monitoring industry, holding approximately 20% of the global share. The region's expansion is driven by a significant rise in diabetes prevalence, urbanization, and increasing disposable incomes. China and India are the largest markets, together accounting for nearly 15% of the total market. Government initiatives aimed at improving healthcare access and diabetes management are also contributing to this growth trajectory.

The competitive landscape in Asia-Pacific is evolving, with both multinational corporations and local players vying for market share. Key players like Terumo and Ascensia Diabetes Care are focusing on innovative solutions tailored to local needs. The increasing adoption of digital health technologies and mobile applications for diabetes management is also shaping the market. As awareness about diabetes care grows, the demand for advanced monitoring devices is expected to rise significantly in the coming years.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually emerging in the blood glucose monitoring market, holding about 5% of the global share. The growth is primarily driven by increasing diabetes prevalence and rising healthcare investments. Countries like South Africa and the UAE are leading the market, contributing significantly to the overall growth. However, challenges such as limited healthcare infrastructure and high costs of advanced monitoring devices hinder market expansion.

The competitive landscape in this region is characterized by a mix of international and local players. Companies like Sanofi are making strides in providing affordable solutions tailored to the local market. The increasing focus on healthcare reforms and partnerships with international organizations aim to improve diabetes care. As awareness about diabetes management grows, the demand for effective monitoring solutions is expected to increase, albeit at a slower pace compared to other regions.

Blood Glucose Monitoring Market Regional Image

Key Players and Competitive Insights

The Blood Glucose Monitoring Market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of diabetes globally. Key players such as Abbott (US), Roche (CH), and Dexcom (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Abbott (US) focuses on innovation, particularly with its FreeStyle Libre system, which has revolutionized continuous glucose monitoring (CGM) through its user-friendly design and real-time data capabilities.

Roche (CH), on the other hand, emphasizes partnerships and collaborations, aiming to integrate its Accu-Chek products with digital health platforms to provide comprehensive diabetes management solutions. Dexcom (US) is heavily invested in digital transformation, leveraging data analytics to improve patient outcomes and streamline healthcare provider interactions. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and patient-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs.

The global market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive innovation. This competitive structure allows for a diverse range of products and services, catering to various consumer needs while fostering an environment ripe for collaboration and strategic partnerships.

In August 2025, Abbott (US) announced the launch of its next-generation FreeStyle Libre 3 system, which boasts improved accuracy and a smaller sensor size. This strategic move is likely to reinforce Abbott's leadership in the CGM segment, as it addresses consumer demand for more discreet and efficient monitoring solutions. The introduction of this product not only enhances patient experience but also positions Abbott to capture a larger share of the growing market for continuous glucose monitoring.

In September 2025, Roche (CH) entered a strategic partnership with a leading telehealth provider to integrate its Accu-Chek devices with remote monitoring capabilities. This collaboration is indicative of Roche's commitment to digital health solutions, allowing for real-time data sharing between patients and healthcare providers. Such integration is expected to improve patient adherence to treatment plans and enhance overall diabetes management, thereby solidifying Roche's competitive edge in the market.

In October 2025, Dexcom (US) unveiled its latest software update, which incorporates artificial intelligence to provide personalized insights for users. This advancement reflects Dexcom's focus on leveraging technology to enhance user engagement and improve health outcomes. By integrating AI into its monitoring systems, Dexcom not only differentiates itself from competitors but also aligns with the broader trend of digitalization in healthcare, which is increasingly becoming a critical factor in patient care.

As of October 2025, the Blood Glucose Monitoring Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing product offerings and expanding market reach. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive advantage in an ever-evolving market.

Key Companies in the Blood Glucose Monitoring Market include

Industry Developments

Recent developments in the Blood Glucose Monitoring Market indicate a significant shift towards innovative technology and increased demand for continuous glucose monitoring systems. Companies like Abbott Laboratories and Dexcom have gained traction with their advanced monitoring devices, offering improved accuracy and ease of use, which is driving market growth.

In September 2023, acquired a minority stake in a technology firm focused on diabetes management, indicating their commitment to expanding their product portfolio.

Growth in market valuation is influenced by rising diabetes prevalence globally, with the International Diabetes Federation reporting a surge in cases. The expansion in emerging markets, coupled with increased investments in diabetes care from companies such as Johnson and Johnson and Bayer, reflects the growing emphasis on addressing chronic conditions.

Regulatory certifications and collaborations between tech companies and healthcare firms continue to shape the landscape, underlining the competitive nature of the industry.

Future Outlook

Blood Glucose Monitoring Market Future Outlook

The Blood Glucose Monitoring Industry size is projected to reach USD 45.46 billion by 2035, growing at a CAGR of 8.35%, driven by technological advancements, increasing diabetes prevalence, and rising health awareness.

New opportunities lie in:

Development of integrated mobile health applications for real-time monitoring.
Expansion of telehealth services for remote patient management.
Investment in AI-driven predictive analytics for personalized treatment plans.

By 2035, the market is expected to be robust, driven by innovation and increased consumer demand.

Market Segmentation

Blood Glucose Monitoring Market Type Outlook

Self-Monitoring Blood Glucose Devices
Continuous Glucose Monitoring Devices
Blood Glucose Test Strips
Lancets

Blood Glucose Monitoring Market End User Outlook

Hospitals
Homecare Settings
Ambulatory Surgical Centers

Blood Glucose Monitoring Market Technology Outlook

Electrochemistry
Optical Method
Transdermal Monitoring

Blood Glucose Monitoring Market Application Outlook

Diabetes Management
Obesity Management
Gestational Diabetes Monitoring

Report Scope

MARKET SIZE 2024	18.81(USD Billion)
MARKET SIZE 2025	20.38(USD Billion)
MARKET SIZE 2035	45.46(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.35% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Abbott (US), Roche (CH), Medtronic (US), Dexcom (US), Bayer (DE), Johnson & Johnson (US), Ascensia Diabetes Care (DE), Terumo (JP), Sanofi (FR)
Segments Covered	Product Type, Technology, End Users, Applications, Regional
Key Market Opportunities	Integration of continuous glucose monitoring with digital health platforms enhances patient engagement and data accessibility.
Key Market Dynamics	Technological advancements in blood glucose monitoring devices drive competitive dynamics and enhance patient self-management capabilities.
Countries Covered	North America, Europe, APAC, South America, MEA

Market Highlights

Blood Glucose Monitoring Companies

FAQs

What is the projected market valuation for the Blood Glucose Monitoring Market in 2035?

The Blood Glucose Monitoring Market is projected to reach a valuation of 45.46 USD Billion by 2035.

What was the market valuation for the Blood Glucose Monitoring Industry in 2024?

In 2024, the Blood Glucose Monitoring Industry was valued at 18.81 USD Billion.

What is the expected CAGR for the global market from 2025 to 2035?

The expected CAGR for the global market during the forecast period 2025 - 2035 is 8.35%.

Which segment of the Blood Glucose Monitoring Market is projected to have the highest growth?

The Self-Monitoring Blood Glucose Devices segment is projected to grow from 7.0 USD Billion in 2024 to 17.0 USD Billion by 2035.

What are the key technologies driving the Blood Glucose Monitoring Market?

Key technologies include Electrochemistry, Optical Method, and Transdermal Monitoring, with Electrochemistry projected to grow from 7.08 USD Billion to 17.0 USD Billion.

Which end user segment is expected to dominate the global market?

The Homecare Settings segment is expected to dominate, growing from 8.0 USD Billion in 2024 to 20.0 USD Billion by 2035.

Who are the leading companies in the Blood Glucose Monitoring Industry?

Key players in the market include Abbott, Roche, Medtronic, Dexcom, and Bayer.

What applications are driving demand in the Blood Glucose Monitoring Market?

Diabetes Management is the leading application, projected to grow from 10.0 USD Billion to 24.0 USD Billion by 2035.

What is the projected growth for Blood Glucose Test Strips in the market?

Blood Glucose Test Strips are projected to grow from 4.0 USD Billion in 2024 to 10.0 USD Billion by 2035.

How does the global market compare across different regions?

While specific regional data is not provided, the overall market growth suggests increasing demand across various regions, particularly in homecare settings.

Author

Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

Certified Researchers

Customize Report

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Medical Device Database, European Medicines Agency (EMA) Medical Device Coordination Group (MDCG), International Diabetes Federation (IDF) Diabetes Atlas, American Diabetes Association (ADA) Standards of Care, Centers for Disease Control and Prevention (CDC) Diabetes Statistics Report, National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Biotechnology Information (NCBI/PubMed) diabetes technology publications, World Health Organization (WHO) Global Diabetes Compact, International Organization for Standardization (ISO) 15197 guidelines for blood glucose monitoring systems, European Association for the Study of Diabetes (EASD) clinical guidelines, Diabetes Technology Society (DTS) surveillance studies, and national health ministry reports from key markets. These sources were used to collect diabetes prevalence statistics, regulatory clearance data (510k approvals, CE marks), clinical accuracy studies (ISO 15197 compliance rates), demographic trends in diabetes management, and competitive landscape analysis for self-monitoring blood glucose devices, continuous glucose monitoring systems, blood glucose test strips, lancets, and emerging transdermal monitoring technologies.

Primary Research

To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, and commercial directors from companies that make blood glucose monitoring devices, diagnostic OEMs, and sensor technology suppliers were examples of supply-side sources. diabetic educators, endocrinologists, diabetologists, hospital procurement leads, homecare medical directors, and pharmacy chain category managers from retail pharmacies, ambulatory surgery centers, hospitals, and diabetic care centers were among the demand-side sources. Primary research confirmed CGM and SMBG product pipeline timelines, validated market segmentation across electrochemistry, optical methods, and transdermal technologies, and collected information on clinical adoption patterns, reimbursement dynamics (private payer policies, Medicare/Medicaid coverage), pricing strategies for consumables versus devices, and patient compliance factors in applications such as gestational diabetes monitoring and diabetes management versus obesity.

Primary Respondent Breakdown:

By Designation: C-level Primaries (38%), Director Level (25%), Others (37%)

By Region: North America (38%), Europe (25%), Asia-Pacific (27%), Rest of World (10%)

Market Size Estimation

Global market valuation was derived through revenue mapping, device shipment analysis, and test strip volume modeling. The methodology included:

Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Product mapping across self-monitoring blood glucose devices, continuous glucose monitoring systems ( sensors, transmitters, receivers), blood glucose test strips, and lancets

Technology segmentation analysis across electrochemical biosensors, optical glucose sensing, and non-invasive transdermal monitoring platforms

Analysis of reported and modeled annual revenues specific to diabetes monitoring portfolios, including recurring consumables revenue (test strips, lancets, CGM sensors) versus capital equipment sales

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (diabetes prevalence × diagnosis rate × monitoring frequency × ASP by country/region) and top-down (manufacturer revenue validation, distributor margin analysis) approaches to derive segment-specific valuations for diabetes management, obesity management, and gestational diabetes monitoring applications across hospital, homecare, and ambulatory surgical center end-user settings

This methodology specifically incorporates diabetes-focused regulatory pathways (FDA 510k for Class II medical devices, ISO 15197 accuracy standards), diabetes epidemiology data sources (IDF Atlas), and BGM-specific stakeholder interviews (endocrinologists vs. dermatologists, diabetes educators vs. aesthetic practitioners) while maintaining the structural format you requested.